Company: MGLD
Filing Date: 2025-01-27
Form Type: 424B5
Source: 0001493152-25-003788
Chunk: 1

Company: Marygold Companies, Inc.
Filing Date: 2025-01-27
Form: 424B5
Chunk 1
---
 our securities should consider.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

|                                            |     | Per share |        |   |     | Total |           |   |
|:-------------------------------------------|:----|:----------|-------:|:--|:----|:------|----------:|:--|
| Public offering price                      |     | $         |  1.100 |   |     | $     | 2,255,000 |   |
| Underwriting Discounts and Commissions (1) |     | $         | (0.088 | ) |     | $     |  (180,400 | ) |
| Proceeds, before expenses, to us           |     | $         |  1.012 |   |     | $     | 2,074,600 |   |

| (1) | See                                                                               
 “Underwriting” for a description of the compensation payable to the underwriters. |

We have granted the underwriters an option for 45 days from the date of this prospectus supplement to purchase an additional 307,500 shares of our common stock. If the underwriters exercise this option, the total underwriting discounts and commissions payable by us will be $207,460 and the total net proceeds to us, before expenses, will be $2,385,790.

The underwriters expect to deliver the shares of common stock against payment in New York, New York, on or about January 27, 2025.

<div align='center'>MAXIM GROUP LLC

The date of this prospectus supplement is January 27, 2025.</div>

<div align='center'>TABLE OF CONTENTS

Prospectus Supplement</div>

| About this Prospectus Supplement                                                    | S-3  |
| Cautionary Note Regarding Forward-Looking Statements                                | S-4  |
| Prospectus Supplement Summary                                                       | S-5  |
| The Offering                                                                        | S-8  |
| Risk Factors                                                                        | S-9  |
| Use of Proceeds                                                                     | S-13 |
| Dividend Policy                                                                     | S-13 |
| Dilution                                                                            | S-14 |
| Description of Securities We Are Offering                                           | S-15 |
| Certain United States Federal Income Tax Considerations                             | S-16 |
| Underwriting